Grow Therapy Stock
| Valuation | $3B1 |
| Valuation Date | Mar 3, 2026 |
| Implied Valuation | $3.19B |
| Last Price | $10.44 |
| 52-Week High | $11.08 |
| 52-Week Low | $9.43 |
| YTD Return | +0.38% |
| 1-Year Return | -5.78% |
| 3-Year Return | n/a |
| Total Funding | $328M2 |
| Latest Round Amount | $150M3 |
| Latest Round | Series D |
| Funding Rounds | 4 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | $1B4 |
| Revenue Type | 2025 |
| P/S Ratio | 3.0 |
About Grow Therapy
Grow Therapy is a mental health platform that helps independent therapists and psychiatrists run insurance-covered practices and connects patients to in-network talk therapy and medication management, in person or online. The company provides practice tools such as credentialing, billing, referrals, scheduling and an EHR, plus clinically guided AI note-taking and between-session tools in its patient app. Grow Therapy makes money by delivering insurance-reimbursed care through its provider network and by partnering with health plans, employers and health systems that send members to that network.
Invest in Grow Therapy
Grow Therapy is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Hiive.
Hiive is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on HiiveStock Analysis may be compensated for user sign-ups through Hiive links. Hiive is not affiliated with Stock Analysis. Securities offered by Hiive Markets Limited, member of FINRA/SIPC.
Related Companies
News
Grow Therapy and Stanford University launch AI research partnership
Grow Therapy partnered with Stanford University to develop evidence-based standards for the safe use of artificial intelligence in mental health care, led by Principal Investigator Jonathan Chen, MD.
Grow Therapy and Stanford University Launch Research Partnership to Establish Clinical Safety Standards in AI for Mental Health
Grow Therapy announced a research partnership with Stanford to develop evidence-based safety standards for AI in mental health, using de-identified cases from Grow's AI coach screening systems.
Grow Therapy Introduces AI Coach With Clinician Oversight to Support Clients Between Therapy Sessions
Grow launched an in-app AI coach for between-session support with clinician oversight and automated safety scoring, expanding nationally after a phased rollout.
Grow Therapy partners with Amazon to provide employee mental health benefits
Grow Therapy announced a partnership with Amazon to redesign the company's U.S. Employee Assistance Program for over one million full-time employees, offering six no-cost therapy sessions and a pathwa...
Grow Therapy Partners With Amazon to Provide Employee Mental Health Benefits
Grow partnered with Amazon to redesign the company's U.S. EAP so employees can start with no-cost EAP sessions and continue with the same provider under insurance.
Grow Therapy Appoints Seth Bressack Chief Financial Officer
Grow named former Shopify finance executive Seth Bressack as its first CFO following the Series D and as it scales employer and health-system partnerships.
Grow Therapy Raises $150M to Expand Employer, Health System Partnerships
MedCity News reported Grow will use Series D proceeds to expand employer-sponsored benefits, primary-care integrations such as Circle Medical, and AI product development.
Grow Therapy raises $150M to expand mental health access
Grow Therapy closed a $150 million Series D to connect insurers, employers, and health systems to integrated mental health care.
Grow Therapy Raises $150 Million in Series D as It Solidifies New Flagship Partnerships
Grow announced a $150 million Series D led by TCV and Goldman Sachs Alternatives, with new capital aimed at employer benefits, health-system integrations and AI tools.
Mental Health Startup Grow Therapy Hits $3 Billion Valuation
Bloomberg reported Grow Therapy reached a $3 billion valuation with its $150 million Series D led by existing investors TCV and Goldman Sachs Alternatives.
With $1B in Revenue, Grow Therapy Lands $150M Series D
Behavioral Health Business covered the Series D, citing about $1 billion in company revenue and noting recent acquisitions of Neosync and Tenor Therapy.
Grow Therapy Buys AI-Scribe Tool Tenor Therapy
Grow acquired Tenor Therapy, a HIPAA-compliant AI clinical documentation tool, and said Tenor's standalone product would be wound down into Grow's platform.
Grow Therapy Names New Leaders in Marketing, Data & Design to Power Next Chapter
Grow appointed Marshall Ball as SVP of Marketing, Gene Tabach as VP of Data, and Evie Alexander as VP of Design amid rapid growth and AI product expansion.
Grow Therapy Raises the Privacy Bar in Mental Health
Grow announced it acquired Neosync to strengthen data anonymization and synthetic-data capabilities for privacy-safe analytics in mental health care.
Grow Therapy Unveils AI-Powered Between-Session Reflections to Deepen Therapy Insights
Grow launched Between-Session Reflections, an AI-assisted journaling feature that helps clients summarize themes for their therapist before the next visit.
Grow Therapy Launches AI-assisted Clinical Tools to Enhance Client and Provider Experience
Grow introduced optional AI-assisted session notes for therapists and visit summaries for clients, both requiring consent and clinician review before use.
Exclusive: Sequoia Leads $88M Grow Therapy Round
Axios reported Grow raised an $88 million Series C led by Sequoia Capital as it scaled insurance-covered therapy and provider practice tools.